Endo International | ENDP - Le Bénéfice D'Exploitation



Le Bénéfice D'Exploitation Changement Date
AbbVie USD 4.73B 1.08B 2026-03
Amarin USD -2.26M 564K 2025-12
ANI Pharmaceuticals USD 38.71M 9.58M 2026-03
Bristol-Myers Squibb USD 4.2B 562M 2025-12
Coherus Biosciences USD -39.08M 3.65M 2025-12
Eli Lilly USD 9.78B 792M 2026-03
Heron Therapeutics USD 38K 3.83M 2025-12
Hikma Pharmaceutical USD 348M 161M 2025-12
Ligand Pharmaceuticals USD 60.33M 40.29M 2026-03
Merck USD -1.88B 8.12B 2026-03
Novartis USD 4.24B 171M 2026-03
Pacira USD 4.62M 1.43M 2026-03
Perrigo USD 33.6M 50.8M 2026-03
Pfizer USD 4.99B 340M 2026-03
Phibro Animal Health USD 54.99M 2.36M 2025-12
Supernus Pharmaceuticals USD -35.25M 49.07M 2026-03
Takeda JPY -13.62B 182.44B 2026-03
Teva Pharmaceutical Industries USD 758M 271M 2026-03
Xeris Pharmaceuticals USD 16.77M 10.04M 2025-12
Zoetis USD 865M 30M 2026-03